News and Press Releases
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025
Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025
Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment
Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025
OGT delivers superior MRD detection capabilities with new SureSeq Myeloid MRD Panel
22 January 2025 – New York City, NY, US – Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a...
Category: BioManufacturing
Posted: January 23, 2025
Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK
Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round
Led by Ventura Capital and joined by other investors including Aviva Ventures, the Gates Foundation and Horizons Ventures Funding will be used to accelerate commercialization and further clinical trials of...
Category: Drug Discovery
Posted: January 17, 2025
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics
14 January 2025 – Menlo Park, California US – PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center...
Category:
Posted: January 16, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
QurAlis Invited to Present at 43rd Annual J.P. Morgan Healthcare Conference
7 January 2025 -- Massaschusetts, US -- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring
Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use...
Category: Biotechnology, Other, Pharmaceutical
Posted: December 17, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
